Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Pangamic acid and interstate shipment of pangamic acid on the grounds that pangamic acid and pangamic acid products are unsafe for use and have no known nutritional properties. Pangamic acid's distribution in Canada has been prohibited by the then-named Canadian Food and Drug Directorate. Pangamic acid Pangamic acid, also called pangamate, is the name given to the chemical compound described as "-gluconodimethylamino acetic acid", initially promoted by Ernst T. Krebs, Sr. and his son Ernst T. Krebs, Jr. as a medicinal compound for use in treatment of a wide range of diseases. They also termed this chemical "Vitamin B", though it is